Skip to content

Tenax Therapeutics, Inc.

TENX Nasdaq SEC CIK 34956

Follow Tenax Therapeutics Weekly email: filings, results, news

News

8 stories filed under Tenax Therapeutics, grouped into ongoing threads

Trial

Thread · 3 stories

Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss

Markets 42 d ago 2 sources

William Blair downgrades Tenax Therapeutics stock rating on trial results

Markets 44 d ago 2 sources

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Markets 44 d ago also on III

More coverage

Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics

Markets 15 d ago

Adar1 Capital Management buys $1.8m of Tenax Therapeutics (TENX) shares

Markets 31 d ago

STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study

Markets 45 d ago

Why is Tenax Therapeutics stock collapsing today?

Markets 45 d ago

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

Markets 49 d ago

Next results

OCT31

Q3 2026 results

Saturday · estimated from the filing cadence

Profile

Headquarters: CHAPEL HILL, NC, United States
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 8 stories clustered from the RSS aggregator